Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

GPR40 (FFAR1) is a promising target for the managing type 2 diabetes (T2D). The most advanced GPR40 agonist TAK-875 exhibited satisfactory glucose-lowering effects in phase II and III studies. However, the phase III studies of TAK-875 revealed drug-induced liver injury (DILI). It is unknown whether...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katarzyna Bazydlo-Guzenda, Pawel Buda, Mateusz Mach, Jerzy Pieczykolan, Izabela Kozlowska, Michal Janiszewski, Ewa Drzazga, Jakub Dominowski, Hubert Ziolkowski, Maciej Wieczorek, Shayne Cox Gad
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0bb5f2026cea4ecb8832d48ef5bc4190
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0bb5f2026cea4ecb8832d48ef5bc4190
record_format	dspace
spelling	oai:doaj.org-article:0bb5f2026cea4ecb8832d48ef5bc41902021-12-02T20:08:04ZEvaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.1932-620310.1371/journal.pone.0257477https://doaj.org/article/0bb5f2026cea4ecb8832d48ef5bc41902021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257477https://doaj.org/toc/1932-6203GPR40 (FFAR1) is a promising target for the managing type 2 diabetes (T2D). The most advanced GPR40 agonist TAK-875 exhibited satisfactory glucose-lowering effects in phase II and III studies. However, the phase III studies of TAK-875 revealed drug-induced liver injury (DILI). It is unknown whether DILI is a consequence of a specific GPR40 agonist or is an inherent feature of all GPR40 agonists. CPL207280 is a novel GPR40 agonist that improves diabetes in Zucker Diabetic Fatty (ZDF) rats, Goto Kakizaki (GK) rats and db/db mice. In this report, the DILI-related toxicity of CPL207280 was compared directly with that of TAK-875. In vitro studies evaluating hepatic biliary transporter inhibition, mitochondrial function, and metabolic profiling were performed in hepatocytes from different species. The long term toxicity of CPL207280 was studied in vivo in rats and monkeys. Activity of CPL207280 was one order of magnitude lesser than that of TAK-875 for the inhibition of bile acid transporters. CPL207280 had a negligible effect on the hepatic mitochondria. In contrast to TAK-875, which was metabolized through toxic glucuronidation, CPL207280 was metabolized mainly through oxidation. No deleterious hepatic effects were observed in chronically treated healthy and diabetic animals. The study presents promising data on the feasibility of creating a liver-safe GPR40 agonist. Additionally, it can be concluded that DILI is not a hallmark of GPR40 agonists; it is linked to the intrinsic properties of an individual agonist.Katarzyna Bazydlo-GuzendaPawel BudaMateusz MachJerzy PieczykolanIzabela KozlowskaMichal JaniszewskiEwa DrzazgaJakub DominowskiHubert ZiolkowskiMaciej WieczorekShayne Cox GadPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257477 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Katarzyna Bazydlo-Guzenda Pawel Buda Mateusz Mach Jerzy Pieczykolan Izabela Kozlowska Michal Janiszewski Ewa Drzazga Jakub Dominowski Hubert Ziolkowski Maciej Wieczorek Shayne Cox Gad Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
description	GPR40 (FFAR1) is a promising target for the managing type 2 diabetes (T2D). The most advanced GPR40 agonist TAK-875 exhibited satisfactory glucose-lowering effects in phase II and III studies. However, the phase III studies of TAK-875 revealed drug-induced liver injury (DILI). It is unknown whether DILI is a consequence of a specific GPR40 agonist or is an inherent feature of all GPR40 agonists. CPL207280 is a novel GPR40 agonist that improves diabetes in Zucker Diabetic Fatty (ZDF) rats, Goto Kakizaki (GK) rats and db/db mice. In this report, the DILI-related toxicity of CPL207280 was compared directly with that of TAK-875. In vitro studies evaluating hepatic biliary transporter inhibition, mitochondrial function, and metabolic profiling were performed in hepatocytes from different species. The long term toxicity of CPL207280 was studied in vivo in rats and monkeys. Activity of CPL207280 was one order of magnitude lesser than that of TAK-875 for the inhibition of bile acid transporters. CPL207280 had a negligible effect on the hepatic mitochondria. In contrast to TAK-875, which was metabolized through toxic glucuronidation, CPL207280 was metabolized mainly through oxidation. No deleterious hepatic effects were observed in chronically treated healthy and diabetic animals. The study presents promising data on the feasibility of creating a liver-safe GPR40 agonist. Additionally, it can be concluded that DILI is not a hallmark of GPR40 agonists; it is linked to the intrinsic properties of an individual agonist.
format	article
author	Katarzyna Bazydlo-Guzenda Pawel Buda Mateusz Mach Jerzy Pieczykolan Izabela Kozlowska Michal Janiszewski Ewa Drzazga Jakub Dominowski Hubert Ziolkowski Maciej Wieczorek Shayne Cox Gad
author_facet	Katarzyna Bazydlo-Guzenda Pawel Buda Mateusz Mach Jerzy Pieczykolan Izabela Kozlowska Michal Janiszewski Ewa Drzazga Jakub Dominowski Hubert Ziolkowski Maciej Wieczorek Shayne Cox Gad
author_sort	Katarzyna Bazydlo-Guzenda
title	Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
title_short	Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
title_full	Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
title_fullStr	Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
title_full_unstemmed	Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
title_sort	evaluation of the hepatotoxicity of the novel gpr40 (ffar1) agonist cpl207280 in the rat and monkey.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/0bb5f2026cea4ecb8832d48ef5bc4190
work_keys_str_mv	AT katarzynabazydloguzenda evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT pawelbuda evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT mateuszmach evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT jerzypieczykolan evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT izabelakozlowska evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT michaljaniszewski evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT ewadrzazga evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT jakubdominowski evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT hubertziolkowski evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT maciejwieczorek evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey AT shaynecoxgad evaluationofthehepatotoxicityofthenovelgpr40ffar1agonistcpl207280intheratandmonkey
_version_	1718375224033935360

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

Ejemplares similares